Strata Critical Medical, Inc. (SRTA) Stock Forecast Oct. 14, 2026
Analysis updated on Oct. 14, 2026 (UTC) · Total · absolute moveSwitch to Alpha · Nasdaq
Strata Critical Medical, Inc. (SRTA) stock forecast summary
Our AI ranks Strata Critical Medical, Inc. outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
Strata Critical Medical, Inc. is a small-cap company with a market capitalization of $394M. It ranks number 8 by market capitalization among the 10 Services-Health Services issuers in our coverage with a current forecast. Its ROE of 14.4% is the highest of the 10 peers that report one. Its Net Margin of 19.0% is the highest of the 10 peers that report one.
A per-ticker accuracy statistic for SRTA is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected absolute price move over the horizon, market included. This is the number a price target is built from. Ratings: strong buy ≥ +4.5%, buy ≥ +3.4%, sell < +2.1%, strong sell < +0.8% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-14 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, SRTA included.
Follow SRTA freeSRTA price chart and AI forecast
How SRTA ranks among 4009 stocks
90D Total forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Strata Critical Medical, Inc. (SRTA) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Services-Health Services peers listed below that report each metric.
Valuation & Market
| Metric | SRTA | Rank |
|---|---|---|
| Market Cap | $394M | 8/10 |
| P/E Ratio | 9.79x | – |
| P/B Ratio | 1.41x | 8/9 |
| EPS | $0.43 | – |
| Book Value/Share | $3.16 | – |
| Revenue/Share | $2.40 | – |
| FCF/Share | $-0.55 | – |
Profitability & Margins
| Metric | SRTA | Rank |
|---|---|---|
| ROE | 14.4% | 1/10 |
| ROA | 12.1% | 1/10 |
| ROIC | -6.3% | 7/11 |
| Gross Margin | 18.9% | 6/8 |
| Operating Margin | -8.6% | 7/12 |
| Net Margin | 19.0% | 1/10 |
| EBT Margin | -9.9% | 7/12 |
| Tax Rate | 0.0% | – |
Financial Health
| Metric | SRTA | Rank |
|---|---|---|
| Current Ratio | 2.64x | 4/11 |
| D/E Ratio | 0.19x | 11/12 |
| Financial Leverage | 1.19x | 11/12 |
| Interest Coverage | -4.3x | 8/11 |
| Working Capital | $75M | 5/11 |
Cash Flow
| Metric | SRTA | Rank |
|---|---|---|
| Operating Cash Flow | -$36M | 11/13 |
| Free Cash Flow | -$48M | 8/9 |
| Capital Spending | -$12M | 4/9 |
| OCF Growth YoY | -2886.7% | 8/8 |
| FCF/Sales | -22.8% | 8/9 |
| CapEx/Sales | 5.8% | 2/9 |
Operational Efficiency
| Metric | SRTA | Rank |
|---|---|---|
| Asset Turnover | 0.64x | 11/11 |
| Receivables Turnover | 4.9x | 7/9 |
| Fixed Assets Turnover | 5.2x | 10/10 |
| Days Sales Outstanding | 75 days | 3/9 |
Income Statement
| Metric | SRTA | Rank |
|---|---|---|
| Total Revenue | $211M | 10/11 |
| Operating Income | -$18M | 10/13 |
| Net Income | $40M | 2/11 |
| R&D Expense | $3M | – |
| SG&A Expense | $22M | 10/11 |
| Cost of Goods Sold | $171M | 3/8 |
Dividend & Shareholder Information
| Metric | SRTA | Rank |
|---|---|---|
| Shares Outstanding | 88M | – |
Balance Sheet Highlights (USD millions)
| Total Current Assets | $121M | 36.4% of assets |
| Cash & Short-term Investments | $16M | 4.9% of assets |
| Accounts Receivable | $43M | 13.0% of assets |
| Total Liabilities | $53M | 16.0% of assets |
SRTA quarterly financials and insider trading
Strata Critical Medical, Inc. (SRTA) industry peers
Companies classified under the same SEC industry code as Strata Critical Medical, Inc. (Services-Health Services): 13 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Total) | Market Cap |
|---|---|---|
| SRTA Strata Critical Medical, Inc. | ▲ | $394M |
| LFST Lifestance Health Group, Inc. | ▲ | $4.71B |
| PRVA Privia Health Group, Inc. | ▼ | $2.77B |
| WGS Genedx Holdings Corp. | ▲ | $1.94B |
| PNTG Pennant Group, Inc. | ▶ | $1.40B |
| USPH U S Physical Therapy Inc /Nv | ▼ | $1.27B |
| INNV Innovage Holding Corp. | ▲ | $1.23B |
| OMDA Omada Health, Inc. | ▲ | $1.12B |
| EUDA Euda Health Holdings Ltd | ▼ | $32M |
| DCGO Docgo Inc. | ▲ | $30M |
| ATPC Agape Atp Corp | ▼ | N/A |
| PIII P3 Health Partners Inc. | ▼ | N/A |
| VSEE Vsee Health, Inc. | ▼ | N/A |
Where SRTA sits on the market map
Strata Critical Medical, Inc. (SRTA) stock news
Loading...
Strata Critical Medical, Inc. (SRTA) stock forecast FAQ
What is the Strata Critical Medical, Inc. (SRTA) stock forecast?
Our AI ranks Strata Critical Medical, Inc. outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
How accurate are Strata Critical Medical, Inc. stock predictions?
A per-ticker accuracy statistic for SRTA is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Strata Critical Medical, Inc. forecasts updated?
Strata Critical Medical, Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 14, 2026.
Which companies are Strata Critical Medical, Inc.'s industry peers?
13 issuers in our coverage, SRTA included, share the SEC industry code Services-Health Services. The largest are: Lifestance Health Group, Inc. (LFST), Privia Health Group, Inc. (PRVA), Genedx Holdings Corp. (WGS), Pennant Group, Inc. (PNTG), U S Physical Therapy Inc /Nv (USPH), Innovage Holding Corp. (INNV).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.